|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 01, 2016 ) Thalassemia is a hereditary blood disorder in which a person’s body makes an abnormal form of hemoglobin, which is the protein molecule in red blood cells (RBCs), which carries oxygen. The disorder results in unwarranted damage of red blood cells, which leads to anemia. Anemia is a condition in which the body doesn’t have adequate amount of normal and healthy red blood cells. There are majorly two types of thalassemia based on these proteins known as the Alpha thalassemia and the Beta thalassemia. There is also a third type viz. Sickle beta thalassemia, which is like a combination of sickle cell disease and beta thalassemia.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=725246
Even though it is a rare genetic disorder, the number of people affected by it has been growing with time. While those with thalassemia minor have hardly any threat to their life and only require occasional blood transfusion to sustain, thalassemia major patients need to go for periodic transfusions for a sustained life. In case of infants, thalassemia major often leads to still birth or cause death shortly after the baby’s birth. Presently the only cure for thalassemia is a bone marrow transplantation therapy, which is done mostly for severe cases of thalassemia.
Browse Detail Report With TOC @ http://www.researchmoz.us/global-thalassemia-market-report-2016-edition-report.html
The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific.
The report provides a comprehensive study of global thalassemia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global thalassemia industry is highly competitive consisting of several companies including the Lonza group, Acceleron Pharma, BlueBird Bio and Sangamo Biosciences etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
